Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Generics Bulletin Top 50, Part Three: Final Firms Enjoy Mixed Fortunes

Declines See A Handful Of Players Slide Down The Chart As Others Climb Our Ranking

Executive Summary

In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.

You may also be interested in...



Coherus’s Low List Price Adalimumab Stacking Up PBM And Pharmacy Partnerships

Coherus has made deals with numerous pharmacy benefit managers and pharmacies to bring its low list price Yusimry adalimumab biosimilar to patients, as analysts continue to back Humira originator AbbVie as market leader. 

ANI Revises Its Expectations Up Following Record Revenues

ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.

Beximco Profit Tumble Continues Amid Hostile Macro Climate

Beximco faced another quarter of declining profits despite growing revenue, as external headwinds including increased production costs took their toll on the firm.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel